Eloralintide: indexed trial records
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
This page carries 7 of the 10 records the literature query returned for Eloralintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.
Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.
At a glance
- Class
- Amylin and amylin receptor agonists
- Receptor targets as recorded
- Amylin receptor
- Records indexed here
- 7
- Records returned by the query
- 10
- Publication years covered
- 2025–2026
- Query retrieved
- 2026-10-12
Shape of the indexed record set
| Record class | Records |
|---|---|
| Phase 2 | 1 |
| Phase 1 | 1 |
| Review or synthesis | 4 |
| Not a registered trial record | 1 |
| Study model as assigned | Records |
|---|---|
| other | 4 |
| human trial | 3 |
Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.
Endpoint coverage
| Endpoint | Records for this compound | Records across all compounds in scope |
|---|---|---|
| Body weight and adiposity | 7 | 108 |
| Glycaemic control | 1 | 117 |
| Cardiovascular | 0 | 30 |
| Renal | 0 | 10 |
| Hepatic | 0 | 9 |
| Neurological | 0 | 18 |
Derived record-set tier
Human trial evidence
(INFERRED, derived from record counts)
Basis: 3 of 7 indexed records are interventional human trials by their own assigned publication type.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of
study quality or of consensus, and it does not rank one compound above another.
What the corpus does not carry for this compound
- Identity fields with no source retrieved: uniprot_id, sequence.
- Reported half-life: no source retrieved, so the value reads Unknown.
- Amounts reported in the cited literature: no row recorded.
- Adverse effects reported in the cited literature: no row recorded.
- Long-form mechanism: not written, because no source was read in full.
- Records the query returned that this corpus does not carry: 3.
An absent row records the absence of a retrieved report, never the absence of the thing itself.
Application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
The records
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 7 | pmid:41207310 | 2025 | Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet (London, England) · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Double-Blind Method; Dose-Response Relationship, Drug; Adult |
Phase 1 — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 6 | pmid:41109426 | 2025 | Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Molecular metabolism · research-article, Clinical Trial, Phase I | human trial | Animals; Humans; Rats; Rats, Sprague-Dawley; Obesity; Anti-Obesity Agents; Adult; Middle Aged |
Review or synthesis — 4 records
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 2 | pmid:41747885 | 2026 | Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes Peptides · Review | other | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptides; Islet Amyloid Polypeptide; Receptors, Islet Amyloid Polypeptide |
| 3 | pmid:42175595 | 2026 | Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis Endocrinology, diabetes & metabolism · review-article, Review | other | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Adult; Overweight; Randomized Controlled Trials as Topic; Islet Amyloid Polypeptide |
| 4 | pmid:42452898 | 2026 | Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials Diabetes, obesity & metabolism · research-article, Review | other | Animals; Humans; Obesity; Weight Loss; Anti-Obesity Agents; Clinical Trials as Topic; Islet Amyloid Polypeptide |
| 5 | pmid:42586227 | 2026 | Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs Pharmacological research · Review | other | Animals; Humans; Obesity; Weight Loss; Anti-Obesity Agents; Islet Amyloid Polypeptide; Amylin Receptor Agonists |
Not a registered trial record — 1 record
| No. | Identifier | Year | Record | Model | Subject headings |
|---|---|---|---|---|---|
| 1 | pmid:41559929 | 2026 | Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Diabetes, obesity & metabolism · research-article, Multicenter Study | human trial | Humans; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method; Dose-Response Relationship, Drug |
Where this page sits
Receptor targets
All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.
Review status
- Review tier
- High impact
- State
- Pending qualified review
- Compiled by
- automated pipeline
- Qualified clinical review
- None on record
Why this tier was assigned
- 3 indexed record(s) are interventional human trials
- the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus
Checks the pipeline performed
- every cited source id resolves to a sources[] row on the entity
- every identifier is a well-formed PMID or DOI
- study model derived only from assigned MeSH headings and publication types
- banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
- unknown values render as the literal word Unknown
Checks the pipeline did not perform
- no full text was read
- no clinical appraisal of any study
- no assessment of whether the indexed set is representative of the literature
A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.
Sources
- PubChem Compound Summary for CID 175663130, Eloralintide. PubChem, National Library of Medicine (2026). pubchem:175663130
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:eloralintide
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular metabolism (2025). pmid:41109426
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, obesity & metabolism (2026). pmid:41559929
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310
- Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide. Cardiology in review (2026). pmid:42745233